RELMADA THERAPEUTICS, INC. (OTCMKTS:RLMD) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07.Submission of Matters to a Vote of Security Holders.
On February 27, 2019, Relmada Therapeutics, Inc. (the “Company”) held its 2018 Annual Meeting of Stockholders (the “Annual Meeting”). Of the 29,764,210 shares of the Company’s common stock outstanding and eligible to vote at the Annual Meeting, 18,314,149 shares, or approximately 61.5% of the eligible common stock, were present either in person or by proxy.All matters submitted to a vote of the Company’s stockholders at the Annual Meeting were approved and the director nominee was elected. The final results of the matters voted on at the Annual Meeting are provided below.
Proposal 1: The following individual was elected as a Class I director to hold office for the term described below or until his resignation, or respective successor is elected and qualified:
| Director Name | For | Against | Abstain | Broker Non-Votes |
| Maged Shenouda (Class I, 36 month term) | 15,783,531 | 126,592 | 28,948 | 2,375,078 |
Proposal 2: Marcum LLP was ratified as the Company’s Independent Registered Public Accounting Firm for the fiscal year ending June 30, 2019.
| For: | 18,192,200 |
| Against: | 74,631 |
| Abstained: | 47,318 |
Proposal 3: An amendment to the Company’s 2014 Stock Option and Equity Incentive Plan, as amended, to increase the number of shares authorized to issue under the plan by 4.0 million shares was approved.
| For: | 13,644,050 |
| Against: | 2,281,878 |
| Abstained: | 13,143 |
| Broker Non-Votes: | 2,375,078 |
Proposal 4: An amendment to the Company’s Articles of Incorporation to increase number of authorized shares of common stock by 100 million shares was approved.
| For: | 17,393,096 |
| Against: | 798,929 |
| Abstained: | 122,124 |
| Broker Non-Votes: |
About RELMADA THERAPEUTICS, INC. (OTCMKTS:RLMD)
Relmada Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a pipeline of drug candidates to treat chronic pain. Its product candidates include d-Methadone (dextromethadone, REL-1017), LevoCap ER (REL-1015), BuTab (REL-1028) and MepiGel (REL-1021). Its d-Methadone is an N-methyl-D-aspartate (NMDA) receptor antagonist being developed for the treatment of neuropathic pain. Its REL-1015 is an extended release, abuse deterrent formulation of the opioid analgesic levorphanol, which is pharmacologically differentiated from morphine, oxycodone and other opioids for the management of pain severe enough to require daily, around-the-clock and long-term opioid treatment. REL-1028 represents formulations of oral, modified release buprenorphine being developed for both chronic pain and opioid dependence indications. REL-1021 is a topical dosage form of the local anesthetic mepivacaine for the treatment of painful peripheral neuropathies.